Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting-Reference-Cited by-同舟云学术

Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting

Published:2011-11-16 Issue:12 Volume:27 Page:2335-2342
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Bergenstal Richard M.¹,Garrison Louis P.²,Miller Lesley-Ann³,Hou Likun⁴,Blickensderfer Amy⁵,Zagar Anthony³,Stanley Shelley⁴,Bhargava Anuj⁶,Wade Rolin⁷,Herman William H.⁸

Affiliation:

1. International Diabetes Center at Park Nicollet Minneapolis, MN, USA

2. Department of Pharmacy, University of Washington Seattle, WA, USA

3. Eli Lilly and Company Indianapolis, IN, USA

4. HealthCore, Inc. Wilmington, DE, USA

5. Amylin Pharmaceuticals, Inc. San Diego, CA, USA

6. Iowa Diabetes and Endocrinology Center, Mercy Medical Center Des Moines, IA, USA

7. Cerner Corporation Kansas City, MO, USA

8. Department of Internal Medicine and Epidemiology, University of Michigan Ann Arbor, MI, USA

Publisher

Informa Healthcare

Subject